DOCSLIB.ORG

Use of Antipsychotic Drugs and Lithium in Mania

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Use of Antipsychotic Drugs and Lithium in Mania BRITISHJOURNAL OF PSYCHIATRY %20%2001), 01), 178 %suppl. 41), s14s148^ 8^ s156 Use of antipsychotic drugs and lithium in mania experience over the following 30 years indi- cated that lithium is far short of an ideal treatment, even when administered expertly JOHN COOKSON to `concordant' patients. There is a striking difference between the results of early con- trolled trials and the outcome on lithium in open clinical practice, where a smaller pro- portion of patients appear to be `lithium re- sponders'; some even doubt the validity of the clinical trials %Moncrieff, 1997). The benefits of lithium therapy have to be balanced against the difficulties in its Background Studies highlighting the Mania or a manic episode is a severe phase management ± with poor compliance in pa- difficulties associated withlithium suggest in the course of bipolar disorders, the con- tients with bipolar disorder and the occur- dition termed `manic±depressive illness' by rence of withdrawal mania ± and the risks that the role of antipsychotic drugs and Kraepelin in the 19th century. A contem- of side-effects and toxicity %Cookson, mood stabilisersin bipolardisorder should porary textbookdescribed the difficulty of 1997). The latter includes the possibility be reconsidered. managing a patient with mania ± using of permanent neurological sequelae with drugs of limited efficacy, mainly sedative cerebellar damage %Schou, 1984). Aims Toreview the efficacyandmode or anaesthetic, such as chloral and ur- Since the 1970s anticonvulsant drugs, of action of antipsychotic drugsin mania, ethane, or potentially toxic drugs, such as first carbamazepine and more recently and to consider the differences between potassium bromide. The sedative anticon- valproate and, in open studies, lamotrigine officialguidelines and routine clinical vulsant paraldehyde was also used. With- and topiramate, have displayed antimanic out sedation the patient would need three effects in at least a proportion of patients practice in the use of these agents for or four attendants, skilled in `a certain kind %Dunn%Dunn et aletal, 1998).,1998). mania. of tact', and spacious, safe accommodation %Clouston, 1896). Thomas Clouston stated MethodMethod Review of research, guideline- the need for a drug in mania as follows: MODE OF ACTION OF and practice-basedliterature. ``what we want and have not yet got is a LITHIUM AND THE MOOD medicine that will cause really natural, rest- STABILISERS ResultsResults Guidelines recommend lithium ful, refreshing sleep, and one that will stay or valproate as first-line treatments for or slacken the morbid energising of the Lithium has numerous effects on biological mania, and antipsychotic agents only as brain cells in the convolutions, without systems, especially at high concentrations `adjuncts'for`adjuncts' for agitation, dangerous affecting the appetite or the nutrition.'' %see Wood & Goodwin, 1987). As the Fifty years later the use of bromides re- smallest alkaline cation, lithium can substi- behaviour or psychosis.However, in mained extensive, but barbiturates such as tute for sodium, potassium, calcium and routine practice, antipsychotic drugs are amylobarbitone %amobarbital) were in use, magnesium in biological systems. It pene- often prescribed.The effectiveness of and paraldehyde remained popular %Sargant trates cells via sodium and other channels these agentsinmania hasbeen established & Slater, 1946). Electroconvulsive therapy but is extruded less efficiently than sodium %ECT) was also being used in mania, by the sodium±potassium active transport by several studies; newer atypical following its introduction in 1935. system. Thus, the plasma±cell ratio for compounds demonstrate antimanic The situation changed dramatically, lithium is much lower than that for sodium. efficacy with a reducedincidence of first in 1949 when John Cade in Australia Within the cell, lithium interacts with sys- neurological side-effects. discovered the effects of lithium in mania tems that normally involve other cations, %Cade, 1949), and in 1952 with the devel- including transmitter release and second- Conclusion Antipsychotic drugs are opment of the first antipsychotic pheno- messenger systems, such as adenylate cy- importantinthetreatmentofbipolarimportantinthe treatmentof bipolar thiazine, chlorpromazine. It remained to clase, the phosphoinositol cycle and protein disorder and mania.Future studies should Schou, working in Aarhus, Denmark, to es- kinase C; these actions effectively block tablish the use of lithium in mania on the particular transmitters and hormones. evaluate the long-term efficacy and safety basis of a controlled study %Schou et aletal,, Receptor upregulation is also reduced, ofnewer atypicalantipsychotic agents, and 1954), and by 1968 the prophylactic effi- perhaps accounting for the value of lithium the place of anticonvulsantsincombinationanticonvulsantsin combination cacy of lithium in bipolar disorder was as an adjunct to other drugs. One of the with antipsychoticsin bipolar disorder. established. Cade's discovery can be major sites of action of anticonvulsant regarded as the beginning of the modern drugs is the membrane ionic channels for Declaration of interest J.C. has era of effective drug treatment in psychiatry conductance of cations ± sodium, calcium lectured and been a member of advisory %Shorter, 1997). and potassium; these control the electrical By 1963, the use of lithium in mania excitability of neurons and the release of panels for Janssen,Eli Lilly and Glaxo was recommended for difficult cases, but transmitters %Upton, 1994). Because they Wellcome.He has also run funded trials of haloperidol was considered particularly show selectivity for particular channels, anti- risperidone, olanzapine and lamotrigine. useful %Sargant & Slater, 1963). However, convulsant drugs may alter cation function s14 8 Downloaded from https://www.cambridge.org/core. 02 Oct 2021 at 09:42:27, subject to the Cambridge Core terms of use. USE OF ANTIPSYCHOTIC DRUGS AND LITHIUM IN MANIA in a more specific way than lithium. High corresponding to a `number needed to treat' antipsychotic pharmacotherapy for the re- doses of antipsychotic drugs can also inter- %NNT) %Laupacis et aletal, 1988) of about 4 duction of manic excitement and for extre- fere with these channels, and their actions %95% CI 3±22). Few patients had a return mely unstable bipolar patients. In contrast, could be quantified in the same way as to normal functioning within 3 weeks. the 1994 guidelines of the APA advise the receptor-blocking affinities are %Task Force, Thus, in routine practice for acute mania, use of antipsychotic agents in mania only 1991).1991). both lithium and valproate are useful as ad- as `adjuncts' to mood stabilisers %particu- juncts to antipsychotic drugs, rather than as larly lithium or valproate) or to ECT, when monotherapy. Lithium has a delayed effect, mania is associated with `agitation', dan- RECENT PRACTICE taking a few days to begin, and 2±8 weeks to gerous behaviour or psychosis %American approach its full effect on mania ± some- Psychiatric Association, 1994). These The recognition of the shortcomings of times even longer. This limits lithium as a guidelines recognise also that antipsychotic lithium has required a reconsideration of treatment for acute mania and makes mono- agents or benzodiazepines may be useful to the role of antipsychotic agents and of the therapy risky for all but the mildest cases. `enhance compliance' with mood stabili- so-called `mood stabilisers' %lithium and The study also validated the concept of sers, or while the latter drugs are develop- the anticonvulsants) in bipolar disorder. lithium non-responders, as patients identi- ing their effect. The guidelines do not It was noted that while doses of anti- fied as such before entry to the study define what is meant by `agitation' in the psychotic drugs given to psychiatric in- showed less improvement on lithium than context of mania, and this is ambiguous. patients in a private university centre did did other patients. Carbamazepine is licensed The guidelines appear to have been not increase from 1989 to 1993, there in the UK for use in patients with bipolar based upon four important principles: was a doubling %to 84%) in the proportion disorder for whom lithium is not suitable; of cases prescribed adjunctive treatment %a)%a)MoodMood stabilisers are effective in manic valproate was licensed for use in bipolar ill- with anticonvulsants and a rise to 70% in states generally, although having a ness in the UK in 2001, although widely the number receiving adjunctive lithium delayed action. prescribed before that. %Baldessarini et aletal, 1995).,1995). %b)%b)AntipsychoticsAntipsychotics are beneficial by virtue Patients who respond to lithium tend to The preference of American %New York) of reducing hyperactivity or by seda- be those with classical mania rather than the psychiatrists for high-potency antipsychotics tion, rather than by a more general anti- mixed or schizoaffective form %Himmel- in mania was illustrated in a study by Chou manic effect. hochhoch et aletal, 1976; Goodnick& Meltzer, et aletal %1996) of 528 patients with mania in 1984; Swann et aletal, 1986). Patients with %c)%c)Antipsychotics,Antipsychotics, but not mood stabi- New Yorkstate hospitals in 1990. Ninety- elated-grandiose mania showed a better re- lisers, reduce psychotic symptoms in two per cent received antipsychotic medi- sponse than those with the destructive-para- mania.mania. cation, 61% lithium, 54% both and 22%
Load more

Recommended publications
  • Rediscovering the Art
    Rediscovering the art 18 Current VOL. 1, NO. 12 / DECEMBER 2002 p SYCHIATRY Current p SYCHIATRY of lithium therapy James W. Jefferson, MD s a mood stabilizer for patients with bipo- Distinguished senior scientist lar disorder, lithium was the darling of Madison Institute of Medicine, Inc. U.S. psychiatry from the 1970s to well into the 1990s. It then began an ill-deserved, gradual fall from Clinical professor of psychiatry A grace and today could be considered a pharmaceutical University of Wisconsin Medical School endangered species. But why? Did lithium lose effectiveness? Is it too toxic? Is its side effect burden too heavy? Does it interact adversely with too many medicines? Is it too cumbersome to use? Was it just a Lithium is not a fad whose time came fad whose time came and went—a psychiatric pet rock? Did it fall prey to the marketing might behind patent-protected and went. It is a valuable medication drugs? Was it replaced by more effective and safer drugs? You are partially correct if you checked “all of the that belongs in our arsenal for bipolar above,” because all contain a kernel of truth. At the same disorder. time, each is an exaggeration that does grave injustice to a remarkable medication. In addition, psychiatry appears to pay only lip service to convincing evidence that lithium is the only mood stabilizer that reduces the risk of suicide during long-term treatment.1 Some psychiatrists rationalize that “lithium is too diffi- cult to use, so I never prescribe it.”2,3 My response is simply, “try it, and I think you’ll like it.” Measuring serum lithium concentrations is simple, accurate, and inexpensive.
    [Show full text]
  • 2020 Question Book
    2020 QUESTION BOOK 13TH EDITION WHO WE ARE Welcome to the thirteenth edition of the Ninja’s Guide to PRITE! Loma Linda University Medical Center is located in sunny Southern California. about 60 miles east of Los Angeles. A part of the Adventist Health System, we provide patient care in one of the largest non-profit health systems in the nation. Loma Linda's mission is to excel in medical education, global healthcare, and community outreach, all under a central tenant: "To Make Man Whole." At the Loma Linda Department of Psychiatry, our residents are trained in many diverse patient care settings. As an official World Health Organization Collaboration Center, our department funds resident electives in Global Mental Health at locations around the world. Additionally, our residents can participate in national and international disaster relief on the LLU Behavioral Health Trauma Team. We were proud to welcome our first group of Child and Adolescent Psychiatry fellows in the Summer of 2019 and work collaboratively with 3 other residency programs within the region. Our residency didactic education is constantly evolving based upon resident feedback, and our residents have the opportunity to aid in course development. More than anything, our residency fosters an environment where residents and faculty treat each other like family. Our faculty are dedicated to resident education and professional development. We believe in "taking 'No' off the table", encouraging innovative change, and passionately supporting our residents to achieve anything they set their minds to. For over a decade our residents have volunteered their time to create The Ninja's Guide to PRITE at our Annual Ninja PRITE Workshop.
    [Show full text]
  • Letters to the Editor
    Letters to the Editor Letters to the Editor Need for a New Framework to Understand lactin levels were high (115 mg/L; normal range, 12–30 mg/L). the© MechanismCopyright of All Antipsychotics 2000 PhysiciansAttempts Postgraduate to reduce dosage below Press, 80 mg/day resultedInc. in relapse, with good recovery when dosage was restored. Sir: The advent of atypical neuroleptics has transformed the A SPECT study was performed using a dual-headed camera pharmacologic treatment of schizophrenia. The advent of single and 185 MBq of 123-Iodobenzamide (IBZM). The specific-to- photon emission computed tomography (SPECT) and positron nonspecific binding ratio was measured at 90 minutes postinjec- emission tomography (PET) neuroreceptor imaging makes it tion. The SPECT was performed a week after a PET analysis possible to link biochemical events in the human brain to their was kindly performed in Dr. Kapur’s laboratory while the pa- clinical consequences. Remington and Kapur1 (supplement 10, tient received 90 mg/day of haloperidol. No detectable recep- 1999) have proposed an interesting model based on studies us- tors at this dosage were found with either technique. ing PET that takes in account the serotonin-2/dopamine-2 Our findings lead us to wonder whether there exists a sub- group of chronic patients resistant to conventional and some (5-HT2/D2) occupancy threshold: conventional antipsychotics atypical neuroleptics in normal doses, but who may respond have low 5-HT2/high D2 ratios, olanzapine and risperidone have well to conventional neuroleptics in high doses. Despite a high high 5-HT2/high D2 ratios, clozapine has a high 5-HT2/low D2 2,3 One personal copy maylevel be of printed striatal D occupancy, our patient did not present with ratio, and quetiapine has a low 5-HT2/low D2 ratio.
    [Show full text]
  • Pharmacologyonline 2: 971-1020 (2009) Newsletter Gabriella Galizia
    Pharmacologyonline 2: 971-1020 (2009) Newsletter Gabriella Galizia THE TREATMENT OF THE SCHIZOPHRENIA: AN OVERVIEW Gabriella Galizia School of Pharmacy,University of Salerno, Italy e-mail: [email protected] Summary The schizophrenia is a kind of psychiatric disease, characterized by a course longer than six months (usually chronic or relapsing), by the persistence of symptoms of alteration of mind, behaviour and emotion, with such a seriousness to limitate the normal activity of a person. The terms antipsychotic and neuroleptic define a group of medicine principally used to treat schizophrenia, but they are also efficacious for other psychosis and in states of psychic agitation. The antipsychotics are divided into two classes: classic or typical and atypical. The paliperidone, the major metabolite of risperidone, shares with the native drug the characteristics of receptoral bond and of antagonism of serotonin (5HT2A) and dopamine (D2). It's available in a prolonged release formulation and it allows the administration once daily. Besides, the paliperidone has a pharmacological action independent of CYT P450 and in such way a lot of due pharmacological interactions would be avoided to interference with the activity of the CYP2D6, that is known to have involved in the metabolism of the 25% of the drugs of commune therapeutic employment. Introduction The schizophrenia has been a very hard disease to investigate by the research. This is not surprising because it involves the most mysterious aspects of human mind, as emotions and cognitive processes. According to scientific conventions, the schizophrenia is a kind of psychiatric disease, characterized by a course longer than six months (usually chronic or relapsing), by the persistence of symptoms of alteration of mind, behaviour and emotion, with such a seriousness to limitate the normal activity of a person.
    [Show full text]
  • The Dual Effect of Lithium on Inflammatory Bowel Disease and Bipolar Disorder: a Review
    ISSN: 2638-3535 Madridge Journal of Clinical Research Review Article Open Access The Dual Effect of Lithium on Inflammatory Bowel Disease and Bipolar Disorder: A Review Gabriel DeSouza, Halford G Warlick IV, and Vincent S Gallicchio* Department of Biological Sciences, Clemson University, Clemson, South Carolina, USA Article Info Abstract *Corresponding author: Lithium has been the gold standard for treatment of bipolar disorder since the mid- Vincent S Gallicchio 20th century. Lithium, at low doses, gained popularity as the first-line treatment of this Department of Biological Sciences disorder. Eventually, lithium became part of many successful treatment plans for bipolar 122 Long Hall Clemson University and depressed patients, leading to more focused research on basic and applied Clemson, South Carolina pharmacological effects of this drug. However, the evidence that lithium can reduce USA inflammation by inhibiting glycogen synthase kinase 3 – beta (GSK3β) enzyme which is E-mail: [email protected] linked to autoimmune and inflammatory disorders, and cancer is still emerging. Therefore, this review examines whether inflammatory conditions such as Inflammatory Received: April 19, 2019 Accepted: November 27, 2019 Bowel Disease (IBD) have a higher occurrence rate of mental illness in comparison to the Published: December 6, 2019 population presenting with IBD without the co-pathology of mental illness. This investigation explored lithium’s beneficial effects in IBD when evaluated either in animal Citation: DeSouza G, Warlick IV HG, models or in IBD patients with or without chronic mental illness. Further research must Gallicchio VS. The Dual Effect of Lithium on be conducted to evaluate for significant evidence of its antipsychotic and anti- Inflammatory Bowel Disease and Bipolar Disorder: A Review.
    [Show full text]
  • Potential Drug-Drug Interactions and Adverse Drug Reactions Associated with Hydroxychloroquine
    Original Article Potential Drug-drug Interactions and Adverse Drug Reactions Associated with Hydroxychloroquine Arjun Singh1, Richa Chaudhary1, Prayas Verma2, Nilanchal Trivedi3,*, Md. Shamim4 1Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, TMU, Moradabad, Uttar Pradesh, INDIA. 2Teerthanker Mahaveer Dental College and Research Centre, TMU Moradabad, Uttar Pradesh, INDIA. 3Department of Pharmacology, Teerthanker Mahaveer College of Pharmacy, TMU, Moradabad, Uttar Pradesh, INDIA. 4LCP College of Pharmacy Baghpat, Abdul Kalam Technical University (AKTU), Uttar Pradesh, INDIA. ABSTRACT Introduction: COVID-19 is a pandemic disaster and a health emergency of prime focus for all the world economies. Various prophylactic treatments are considered to combat the disease. Hydroxychloroquine drug is one such option that is given much attention as an armor against SARS COV-2 pandemic. Evaluation and assessment of drug interactions and ADRs is required from ethical concern to justify the use of HCQ on such large scale. Methods: We have performed an analysis of HCQ drug interactions on Micromedex®. We have reviewed literature of HCQ pharmacokinetic properties, ADRs/ ADEs and toxicities associated with the use of HCQ drug on PubMed, Google Scholar and CDC database. Results: There are around 180 drug interactions possible with HCQ. Out of them 13 are of contraindicated severity level and other 165 are of major severity and 2 of them are moderately severe. Most of the interactions are coupled with QT prolonging agents (170), Cardiac arrhythmias is possible with the concomitant use of at least 2 drugs, 4 drugs leads to Torsade de points. System organ level ADRs are also evaluated along with various precautions, warnings and contraindications.
    [Show full text]
  • Screening of 300 Drugs in Blood Utilizing Second Generation
    Forensic Screening of 300 Drugs in Blood Utilizing Exactive Plus High-Resolution Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Forensic Toxicology use Only Drugs analyzed Compound Compound Compound Atazanavir Efavirenz Pyrilamine Chlorpropamide Haloperidol Tolbutamide 1-(3-Chlorophenyl)piperazine Des(2-hydroxyethyl)opipramol Pentazocine Atenolol EMDP Quinidine Chlorprothixene Hydrocodone Tramadol 10-hydroxycarbazepine Desalkylflurazepam Perimetazine Atropine Ephedrine Quinine Cilazapril Hydromorphone Trazodone 5-(p-Methylphenyl)-5-phenylhydantoin Desipramine Phenacetin Benperidol Escitalopram Quinupramine Cinchonine Hydroquinine Triazolam 6-Acetylcodeine Desmethylcitalopram Phenazone Benzoylecgonine Esmolol Ranitidine Cinnarizine Hydroxychloroquine Trifluoperazine Bepridil Estazolam Reserpine 6-Monoacetylmorphine Desmethylcitalopram Phencyclidine Cisapride HydroxyItraconazole Trifluperidol Betaxolol Ethyl Loflazepate Risperidone 7(2,3dihydroxypropyl)Theophylline Desmethylclozapine Phenylbutazone Clenbuterol Hydroxyzine Triflupromazine Bezafibrate Ethylamphetamine Ritonavir 7-Aminoclonazepam Desmethyldoxepin Pholcodine Clobazam Ibogaine Trihexyphenidyl Biperiden Etifoxine Ropivacaine 7-Aminoflunitrazepam Desmethylmirtazapine Pimozide Clofibrate Imatinib Trimeprazine Bisoprolol Etodolac Rufinamide 9-hydroxy-risperidone Desmethylnefopam Pindolol Clomethiazole Imipramine Trimetazidine Bromazepam Felbamate Secobarbital Clomipramine Indalpine Trimethoprim Acepromazine Desmethyltramadol Pipamperone
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • A History of the Pharmacological Treatment of Bipolar Disorder
    International Journal of Molecular Sciences Review A History of the Pharmacological Treatment of Bipolar Disorder Francisco López-Muñoz 1,2,3,4,* ID , Winston W. Shen 5, Pilar D’Ocon 6, Alejandro Romero 7 ID and Cecilio Álamo 8 1 Faculty of Health Sciences, University Camilo José Cela, C/Castillo de Alarcón 49, 28692 Villanueva de la Cañada, Madrid, Spain 2 Neuropsychopharmacology Unit, Hospital 12 de Octubre Research Institute (i+12), Avda. Córdoba, s/n, 28041 Madrid, Spain 3 Portucalense Institute of Neuropsychology and Cognitive and Behavioural Neurosciences (INPP), Portucalense University, R. Dr. António Bernardino de Almeida 541, 4200-072 Porto, Portugal 4 Thematic Network for Cooperative Health Research (RETICS), Addictive Disorders Network, Health Institute Carlos III, MICINN and FEDER, 28029 Madrid, Spain 5 Departments of Psychiatry, Wan Fang Medical Center and School of Medicine, Taipei Medical University, 111 Hsin Long Road Section 3, Taipei 116, Taiwan; [email protected] 6 Department of Pharmacology, Faculty of Pharmacy, University of Valencia, Avda. Vicente Andrés, s/n, 46100 Burjassot, Valencia, Spain; [email protected] 7 Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University, Avda. Puerta de Hierro, s/n, 28040 Madrid, Spain; [email protected] 8 Department of Biomedical Sciences (Pharmacology Area), Faculty of Medicine and Health Sciences, University of Alcalá, Crta. de Madrid-Barcelona, Km. 33,600, 28871 Alcalá de Henares, Madrid, Spain; [email protected] * Correspondence: fl[email protected] or [email protected] Received: 4 June 2018; Accepted: 13 July 2018; Published: 23 July 2018 Abstract: In this paper, the authors review the history of the pharmacological treatment of bipolar disorder, from the first nonspecific sedative agents introduced in the 19th and early 20th century, such as solanaceae alkaloids, bromides and barbiturates, to John Cade’s experiments with lithium and the beginning of the so-called “Psychopharmacological Revolution” in the 1950s.
    [Show full text]
  • Grief, Traumatic Loss and Depression
    1 GRIEF, TRAUMATIC LOSS AND DEPRESSION Talk to Victorian Branch RANZCP 11TH JUNE 2003 Thank you for inviting me to talk about grief, traumatic loss and depression. As so often happens, after a topic is decided, one thinks of a better one. So I would like to add two word to the beginning “Loss and”, to read “Loss and Grief, Traumatic Loss and Depression”. That will give you a better taste for what is to come. Depression is perhaps the most common diagnosis in psychiatry. It is the most bandied about word in the community, relating to mental illness. With so many experts, starting with Jeff Kennett, having so much to say about it, I thought I may have been invited to speak from the point of view of my age, having spanned a career living with depression (other people’s I mean). However, what I will contribute that may be special is a view of depression from the perspective of traumatology. This will tie together loss, grief, traumatic loss and depression. Road map for this talk I will describe briefly the developing thoughts on depression to which I was exposed over the years. 2 I will note the emergence of loss, grief and trauma as relevant to the loss-depression process. Next, I will attempt to make sense of how loss, grief, trauma and depression hang together and the dynamics involved. I will suggest that grief is the most adaptive response to loss, while depression occurs when grief does not occur, often in traumatic loss situations. Some have said that depression is a hodge podge of symptoms and consists of a number of disorders.
    [Show full text]
  • PDF Download Finding Sanity: John Cade, Lithium and the Taming Of
    FINDING SANITY: JOHN CADE, LITHIUM AND THE TAMING OF BIPOLAR DISORDER PDF, EPUB, EBOOK Greg De Moore,Ann Westmore | 304 pages | 01 Apr 2017 | Allen & Unwin | 9781760113704 | English | St Leonards, Australia Finding Sanity: John Cade, Lithium and the Taming of Bipolar Disorder PDF Book Fitzroy, Victoria , Australia. This is prelude to an entire nine-page case history of Bill Brand, the first of ten patients John Cade would treat with lithium. If significant kidney problems show up in the initial testing, lithium should be prescribed only with great care and close monitoring. Transcranial Magnetic Stimulation vs. This time he failed to benefit from ECT. Bipolar Disorder With Anxious Distress. Following the British tradition John completed a postdoctoral degree in medicine. Managing symptoms and preventing complications begins with a thorough knowledge of your illness. There are 2 toxic substances in urine: urea and uric acid. Random House, Gitlin M. One was a female patient in her late 50s who had developed side effects within a day of starting treatment. When first seen as outpatients people were required to bring a relative or significant other with them who was interviewed separately to provide a broad perspective. My fellow resident David Taylor and I befriended George, a lonely bachelor, and welcomed him into our homes, catering to a gargantuan omnivorous appetite. Mercifully Jack recovered fully, possibly due to the discovery of a new drug, cortisone. Are your symptoms caused by something else? Mood Disorders Society of Canada. While he was convalescing, John fell in love with one of his nurses, Jean. For his contribution to psychiatry, he was awarded a Kittay International Award in with Mogens Schou from Denmark , and he was invited to be a Distinguished Fellow of the American College of Psychiatrists.
    [Show full text]
  • Clinical Use of Lithium Salts: Guide for Users and Prescribers
    Tondo et al. Int J Bipolar Disord (2019) 7:16 https://doi.org/10.1186/s40345-019-0151-2 REVIEW Open Access Clinical use of lithium salts: guide for users and prescribers Leonardo Tondo1,2,3* , Martin Alda4, Michael Bauer5, Veerle Bergink6,7, Paul Grof8, Tomas Hajek4, Ute Lewitka5, Rasmus W. Licht9,10, Mirko Manchia11,12, Bruno Müller‑Oerlinghausen13, René E. Nielsen9,10, Marylou Selo14, Christian Simhandl15, Ross J. Baldessarini1,2 and for the International Group for Studies of Lithium (IGSLi) Abstract Background: Lithium has been used clinically for 70 years, mainly to treat bipolar disorder. Competing treatments and exaggerated impressions about complexity and risks of lithium treatment have led to its declining use in some countries, encouraging this update about its safe clinical use. We conducted a nonsystematic review of recent research reports and developed consensus among international experts on the use of lithium to treat major mood disorders, aiming for a simple but authoritative guide for patients and prescribers. Main text: We summarized recommendations concerning safe clinical use of lithium salts to treat major mood dis‑ orders, including indications, dosing, clinical monitoring, adverse efects and use in specifc circumstances including during pregnancy and for the elderly. Conclusions: Lithium continues as the standard and most extensively evaluated treatment for bipolar disorder, espe‑ cially for long‑term prophylaxis. Keywords: Bipolar disorder, Blood testing, Dosing, Lithium, Side‑efects Historical introduction and efective treatment was not immediately adopted In 1949, John Cade (1929–1996), an Australian psychia- by psychiatry. As Cade himself observed, “a discovery trist, serendipitously initiated a new era in psychiatric by an unknown psychiatrist without research training, treatment by using lithium carbonate to treat mania.
    [Show full text]